Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Significance The study demonstrates that V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint that is preferentially expressed at higher levels in pancreatic cancer. The study gives a detailed analysis of immune infiltration in primary and metastatic pancreatic tumors compared with melanoma, which differs in its tumor/stromal distribution. Our data indicate that human pancreatic tumors express CD68 + macrophages and highlight the inhibitory checkpoint molecule VISTA as a potential immunotherapeutic target in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VISTA is another inhibitory checkpoint molecule that is largely and constitutively expressed on myeloid cells and also on T cells, and NK cells (Blando et al., 2019; Gao et al., 2017; Wang et al., 2019a).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Blando et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“targeting the PD-1–PD-L1 axis has not been successful in pancreatic cancer (3, 4, 8).”
BackgroundResultWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Self-citationMcGuire, S. (2016) · Advances in Nutrition · doi:10.3945/an.116.012211 · Cited by 1,898
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Cited by
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationNovel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
“, VISTA was regard as a promising target for patients with pancreatic cancer [120] and the HMBD-002, a novel antiVISTA antibody developed by Hummingbird Bioscience, have received a financial assistance from Cancer Prevention and Research Institute of Texas (CPRIT) with the plan to initiate clinical trials in 2020.”
BackgroundChallenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Bockorny, B., Semenisty, V., Macarulla, T., Borazanci, E., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 557
Metadata
- Authors
- Blando, J., Sharma, A., Higa, M. G., Zhao, H., Vence, L., Yadav, S. S., Kim, J., Sepulveda, A. M., Sharp, M., Maitra, A., Wargo, J., Tetzlaff, M., Broaddus, R., Katz, M. H. G., Varadhachary, G. R., Overman, M., Wang, H., Yee, C., Bernatchez, C., Iacobuzio-Donahue, C., Basu, S., Allison, J. P., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Janssen Oncology Therapeutic Area, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 19477;
- David Rubenstein Pancreatic Cancer Research Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-01-11
- Volume
- 116
- Issue
- 5
- Pages
- 1692-1697
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6358697
- OpenAlex
- W2910310961
- Cited by
- 334
- References
- 42
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 46 · 2023: 45 · 2022: 50 · 2021: 56 · 2020: 56 · 2019: 26
- FWCI
- 19.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA1633793)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- VISTA, immune checkpoint, pancreatic cancer, melanoma, tumor immune infiltrate, CD68+ macrophages, tumor stroma, metastatic pancreatic tumor, immunotherapy targets
- MeSH terms
- Adenocarcinoma, Humans, Immunotherapy, Lymphocyte Activation, Melanoma, Pancreatic Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Carcinoma, Pancreatic Ductal, Tumor Microenvironment, B7 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. https://app.cochat.ai/papers/10.1073/pnas.1811067116
- The paper
- Blando, J., Sharma, A., Higa, M. G., Zhao, H., Vence, L., Yadav, S. S., Kim, J., Sepulveda, A. M., Sharp, M., Maitra, A., Wargo, J., Tetzlaff, M., Broaddus, R., Katz, M. H. G., Varadhachary, G. R., Overman, M., Wang, H., Yee, C., Bernatchez, C., . . . Sharma, P. (2019). Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1811067116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.